08 July 2021 : Clinical Research
Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report
Roger J. Ziętek1BDF, Zbigniew M. Ziętek
123ACE*
DOI: 10.12659/MSM.931597
Med Sci Monit 2021; 27:e931597
Table 1 Sociodemographic and clinical data of patients with benign prostatic hyperplasia in the transurethral microwave thermotherapy (TUMT) and pharmacotherapy (control) groups.
| Examined parameter | Treatment | |
|---|---|---|
| TUMT | Control | |
| Number of patients | 840 | 1040 |
| Age (years) (X±SD) | 76±19 | 79±21 |
| BMI (kg/m) (X±SD) | 27.9±5.1 | 29.9±7.1 |
| Normal weight <25 kg/m) (number; %) | 398 (47%) | 510 (49%) |
| Overweight (>25 kg/m) (number; %) | 442 (53%) | 530 (515) |
| Testosterone (ng/dL) (X±SD) | 412.4±177.1 | 462±122 |
| Prostate volume (mL) (median; 1 quartile; 3 quartile) | 39.2 (29.7; 97.5) | 42.2 (30.7; 77.5) |
| PSA (ng/mL) (median; 1 quartile; 3 quartile) | 6.5 (0.2; 6.4) | 4.5 (0.3; 5.4) |
| Hypertension arterialis (n; %) | 428 (51%) | 551 (53%) |
| Diabetes mellitus (n; %) | 142 (17%) | 208 (20%) |
| Chronic kidney insufficiency (n; %) | 76 (9%) | 98 (9%) |
| Coronary artery disease (n; %) | 159 (19%) | 231 (22%) |
| Respiratory insufficiency (n; %) | 45 (5%) | 75 (7%) |
| Heavy smokers (1 pack cigarettes/day) (n; %) | 159 (19%) | 156 (15%) |
| Hypercholesterolemia (n; %) | 210 (25%) | 333 (32%) |
| X – mean; SD – standard deviation; BMI – body mass index; PSA – prostatic-specific antigen; TUMT – transurethral microwave thermotherapy. | ||